IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence
Abstract
Background: IL-17 pathway inhibitors are established treatments for active psoriatic arthritis (PsA), but comparative evidence within this therapeutic class remains limited. We compared the efficacy, safety, treatment rankings, and certainty of evidence for established and emerging IL-17 pathway inhibitors in adults with active PsA.
Methods: We conducted a PRISMA-compliant systematic review and network meta-analysis. MEDLINE via PubMed, Embase via Ovid, CENTRAL, ClinicalTrials.gov, and the EU Clinical Trials Register were searched from January 1, 2010, to January 18, 2026. Eligible studies were phase 2 or phase 3 randomized controlled trials in adults with PsA. The primary outcome was ACR50 at Weeks 12-16. Secondary outcomes included ACR20, ACR70, PASI90, minimal disease activity, HAQ-DI, safety outcomes, Week-24 outcomes, and descriptive Week-52 outcomes. Frequentist random-effects network meta-analysis was performed; certainty was assessed using CINeMA.
Results: Sixteen RCTs were included. The primary ACR50 network comprised eight RCTs and ten treatment nodes. All active treatments were superior to placebo for ACR50 at Weeks 12-16, with negligible heterogeneity (τ² = 0; I² = 0%) and no important incoherence. Ixekizumab Q2W had the highest ACR50 P-score, followed by bimekizumab 160 mg with loading and ixekizumab Q4W; however, active-treatment confidence intervals overlapped. Secondary outcomes showed consistent improvements in joint, skin, multidomain, and functional…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.